Buy Rating for Cidara Therapeutics: Promising Potential of CD388 in Influenza Prevention
PremiumRatingsBuy Rating for Cidara Therapeutics: Promising Potential of CD388 in Influenza Prevention
24d ago
Ed Arce’s Buy Rating for Cidara Therapeutics Driven by Accelerated CD388 Program and Promising Phase 2b NAVIGATE Study Developments
Premium
Ratings
Ed Arce’s Buy Rating for Cidara Therapeutics Driven by Accelerated CD388 Program and Promising Phase 2b NAVIGATE Study Developments
25d ago
Cidara Therapeutics price target raised to $35 from $24 at H.C. Wainwright
Premium
The Fly
Cidara Therapeutics price target raised to $35 from $24 at H.C. Wainwright
25d ago
Six new option listings and one option delisting on February 26th
PremiumThe FlySix new option listings and one option delisting on February 26th
1M ago
Cidara Therapeutics Announces CFO Transition
Premium
Company Announcements
Cidara Therapeutics Announces CFO Transition
1M ago
Cidara Therapeutics appoints Karbe as CFO
Premium
The Fly
Cidara Therapeutics appoints Karbe as CFO
2M ago
Cidara Therapeutics files to sell 7.04M shares of common stock for holders
PremiumThe FlyCidara Therapeutics files to sell 7.04M shares of common stock for holders
3M ago
Twelve option delistings on December 23rd
Premium
The Fly
Twelve option delistings on December 23rd
3M ago
Cidara Therapeutics initiated with an Outperform at RBC Capital
Premium
The Fly
Cidara Therapeutics initiated with an Outperform at RBC Capital
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100